|
|
|
 Пошук по сайту
Авторизація
Періодика
Партнери
Технічна підтримка
 |
Американський ринок терапії доброякісної гіперплазії передміхурової залози мінімально інвазивним методом (U.S. Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market) Benign prostatic hyperplasia (BPH), or the noncancerous enlargement of the prostate gland, is a common condition associated with aging. While the prostate grows throughout a man’s lifetime, bothersome growth typically begins at age 40, and by approximately age 60 more than half of men will have experienced at least some symptoms of BPH; by age 80, up to 80% to 90% of men become symptomatic. It is estimated that nearly 15 million men in the United States and 30 million men worldwide experience symptoms of BPH; of this number, an estimated 25% require pharmaceutical or surgical treatment. Due to the aging of the population, the number of men with the condition is expected to follow an upward trend. This presents a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe and effective alternative to drugs and invasive surgery, which carry greater risk of undesirable or significant side effects and complications.
Publisher: Medtech Insight
While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively good growth over the next 5 years. Valued at an estimated $147.5 million in 2010, the U.S. minimally invasive benign prostatic hyperplasia therapy systems market is expected to increase at a compound annual rate of 2.4%, with sales reaching more than $166 million in 2015. The largest segment, laser BPH therapy, is expected to drive market growth over the forecast period—expanding at a comparatively higher rate of 4.6%—at the expense of minimally invasive office-based therapies. This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include transurethral microwave thermotherapy (TUMT); transurethral needle ablation (TUNA); holmium laser ablation of the prostate (HoLAP); photoselective vaporization of the prostate (PVP), or Greenlight Laser Therapy; transurethral resection of the prostate (TURP); and other energy-based technologies. TABLE OF CONTENTS EXECUTIVE SUMMARY i. Causes ii. Symptoms iii. Diagnosis iv. Treatment a. Prescription Drugs b. Minimally Invasive Therapy c. Surgery d. Stents v. Minimally Invasive Benign Prostatic Therapy Systems Market a. Procedure Volumes Forecast b. Market Forecast vi. Methodology Exhibit ES-1: The Prostate and Urine Flow Exhibit ES-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia Exhibit ES-3: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015 Exhibit ES-4: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 1. CLINICAL OVERVIEW OF BENIGN PROTATIC HYPERPLASIA 1.1 Causes 1.2 Symptoms 1.3 Diagnosis 1.4 Treatment 1.4.1 Prescription DrugsExhibit 1-1: The Prostate and Urine Flow Exhibit 1-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia 2. MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA THERAPY SYSTEMS 2.1 Transurethral Microwave Thermotherapy 2.1.1 CoreTherm: ProstaLund Operations2.2 Transurethral Needle Ablation: Medtronic 2.3 Laser- and Other Energy-Based Therapies 2.3.1 Holmium Laser Ablation/Enucleation of the Prostate2.4 Prostatic Stents 2.4.1 The Spanner Prostatic Stent: AbbeyMoor Medical2.5 Market Analysis 2.5.1 Procedure Volumes Forecast2.6 Competitive Analysis Exhibit 2-1: Advantages and Disadvantages of Minimally Invasive Therapy for Benign Prostatic Hyperplasia Exhibit 2-2: 2011, Selected Microwave- and Radiofrequency-Based Benign Prostatic Hyperplasia Therapy Systems Exhibit 2-3: The CoreTherm System Exhibit 2-4: Five-Year Clinical Comparison of Symptomatic Reduction in Benign Prostatic Hyperplasia Using the CoreTherm System and Competitive Treatments Exhibit 2-5: The Schelin Catheter Exhibit 2-6: The CoolWave and Targis Systems Exhibit 2-7: The Cooled ThermCath Advance Catheter Exhibit 2-8: Cooled ThermoTherapy, Selected Five-Year Clinical Trial Results Exhibit 2-9: Comparison of Cooled ThermoTherapy with Drug Therapy, Selected Clinical Results Exhibit 2-10: The Prostiva Radiofrequency Therapy System Exhibit 2-11: Holmium Laser Ablation of the Prostate Using the VersaPulse PowerSuite Laser System Exhibit 2-12: Selected Advantages of Holmium Laser Ablation Using the VersaPulse PowerSuite Compared with Photoselective Vaporization Using the GreenLight PV Exhibit 2-13: The GreenLight High Performance System Exhibit 2-14: The GreenLight Xcelerated Performance System Exhibit 2-15: The MoXy Liquid Cooled Fiber Exhibit 2-16: The EVOLVE Laser System Exhibit 2-17: PlasmaButton Vaporization Therapy Exhibit 2-18: Aptocine’s Effects on Tumor Cells, and Selected Benefits of Aptocine Treatment Exhibit 2-19: The Spanner Prostatic Stent Exhibit 2-20: The CoreFlow Soft Stent Exhibit 2-21: Benefits of the UroLume Urethral Stent Exhibit 2-22: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015 Exhibit 2-23: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 Exhibit 2-24: 2010, Benign Prostatic Hyperplasia Laser Therapy Systems Market, Share by Supplier Exhibit 2-25: 2010, Transurethral Microwave Thermotherapy and Transurethral Needle Ablation Systems Market, Share by Supplier 3. COMPANY PROFILES 3.1 American Medical Systems, Inc. 3.2 Boston Scientific Corporation 3.3 Lumenis LTD 3.4 Medtronic, Inc. 3.5 Olympus America/Olympus Corporation 3.6 ProstaLund Operations AB 3.7 Urologix, Inc. Перекладач: translate.google.com |
Новини
03.03.2023 Науково доведено: через смартфони ви можете старіти швидше
24.02.2023 Стимуляція спинного мозку відновлює постінсультну функцію рук 17.02.2023 Вчені відкрили здатність жирної їжі руйнувати мозок 10.02.2023 В Індії розробили неінвазивний тест, який використовує штучний інтелект для виявлення раку молочної залози 01.02.2023 Як спостереження за світанками та заходами сонця впливає на здоров'я – вчені 25.01.2023 Аналіз крові для ранньої діагностики хвороби Альцгеймера розробили вчені 18.01.2023 Людина з серцем свині. Пацієнту вперше пересадили серце тварини 11.01.2023 Вчені пояснили, чому оливкову олію варто пити ложками 21.11.2022 Вчені виявили ще одну причину високого ризику атеросклерозу 18.11.2022 Імплантована помпа доставила протиракові ліки у пухлини мозку 16.11.2022 Шум вночі може бути причиною безсоння та серцево-судинних захворювань 14.11.2022 ЩО ТРЕБА ЗНАТИ ПРО ЦУКРОВИЙ ДІАБЕТ: ТИПИ, СИМПТОМИ, УСКЛАДНЕННЯ 11.11.2022 Виявилося, в епідемії ожиріння винен лише один тип їжі 09.11.2022 Проказа: давня хвороба, здатна регенерувати органи 07.11.2022 "Чарівні гриби" можуть лікувати важку депресію 04.11.2022 Нове випробування пропонує переваги CV з EPA: RESPECT-EPA 02.11.2022 Майже 500 українських медиків завершили навчання з тактичної медицини 01.11.2022 Чи можна людям з діабетом пити алкоголь 31.10.2022 Знайдено овоч, здатний знизити цукор у крові відразу на 20% 28.10.2022 Людська печінка може працювати 100 років   |
